AVIR Atea Pharmaceuticals, Inc.

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

$70.47  -1.35 (-1.88%)
As of 03/03/2021 15:59:01 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Mid cap
Health Care
Biotechnology
USA
USA
10/30/2020
82,616,937
270,367
$5,933,548,415
0.00%
SEC Edgar Online
10-Q
10-K
04683R106
US04683R1068
BLN9Z50

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
-77.55
0.00
33.86%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy